Company overview
Basic information
Company name
Agrupus, MB
Company code
306370123
VAT code
LT100016238212
Registered address
Vilniaus r. sav., Medininkų sen., Medininkų k., Sodų g. 9, LT-13192
Registration date
2023-07-31
Company age: 3 y. 3 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
https://www.agrupus.com
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Retail sale of pharmaceutical products
Ownership form
Private without foreign capital
MB "Agrupus"
Company code: 306370123
Address: Vilniaus r. sav., Medininkų sen., Medininkų k., Sodų g. 9, LT-13192
VAT code: LT100016238212
Description
This description was generated by artificial intelligence.
Agrupus, MB is a private small partnership registered in 2023 and operating in Lithuania as a national private non-financial company. The company is active and is governed by a CEO only. It is classified as privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. Agrupus, MB is based in Medininku k., Medininku sen., Vilniaus r. sav., Vilniaus apskr., at Sodu g. 9, LT-13192. Its main activity is retail sale of pharmaceutical products (EVRK code G.47.73.00).
Financially, the company increased its revenue sharply over the last three financial years. Revenue rose from €1.2K in 2023, during a 153-day period, to €18.9K in 2024 and €127.4K in 2025. Despite this growth, the company remained loss-making, with net profit of -€17.5K in 2023, -€23.4K in 2024 and -€16.2K in 2025. Equity was negative in each year, while liabilities were €19.4K in 2023, €27.3K in 2024 and €18.0K in 2025. Staff data is not provided in the available information.
Financially, the company increased its revenue sharply over the last three financial years. Revenue rose from €1.2K in 2023, during a 153-day period, to €18.9K in 2024 and €127.4K in 2025. Despite this growth, the company remained loss-making, with net profit of -€17.5K in 2023, -€23.4K in 2024 and -€16.2K in 2025. Equity was negative in each year, while liabilities were €19.4K in 2023, €27.3K in 2024 and €18.0K in 2025. Staff data is not provided in the available information.
Download a detailed company report
Make confident decisions with all the information about Agrupus, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.